Condition: Non-small Cell Lung Cancer (NSCLC) · Sponsor: Merck Sharp & Dohme LLC
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona - Phoenix ( Site 0147) | Phoenix, Arizona, United States | Recruiting |
| Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) | Burbank, California, United States | Recruiting |
| Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) | Grand Junction, Colorado, United States | Recruiting |
| Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) | Jacksonville, Florida, United States | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) | Marietta, Georgia, United States | Completed |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0121) | Louisville, Kentucky, United States | Completed |
| New England Cancer Specialists ( Site 0143) | Westbrook, Maine, United States | Recruiting |
| University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144) | Worcester, Massachusetts, United States | Completed |
| Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic - Rochester ( Site 0148) | Rochester, Minnesota, United States | Recruiting |
| Hattiesburg Clinic Hematology/Oncology ( Site 0104) | Hattiesburg, Mississippi, United States | Recruiting |
| Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) | Reno, Nevada, United States | Recruiting |
+ 208 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06170788